Mounjaro vs Zepbound: What's Actually Different

Mounjaro and Zepbound are the same drug: tirzepatide, made by Eli Lilly. The only real difference is the label. Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is approved for chronic weight management and, more recently, obstructive sleep apnea in adults with obesity. The molecule, the mechanism, and the weight-loss potential are identical; what changes is the approved use, the insurance coverage, and the available dose strengths.

This article breaks down what is actually different between the two brands and what is just marketing, so you can have a clearer conversation with your prescriber. It is general education, not medical advice, and Myo is not affiliated with Eli Lilly.

Are Mounjaro and Zepbound the same drug?

Yes. Both Mounjaro and Zepbound contain tirzepatide as the active ingredient. Tirzepatide is a once-weekly subcutaneous injection and a dual agonist, meaning it activates two gut-hormone receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). That dual action is what distinguishes tirzepatide from semaglutide, which targets GLP-1 alone.

A "receptor agonist" is simply a drug that switches on a receptor the way the body's own hormone would. Tirzepatide switching on both GIP and GLP-1 receptors amplifies satiety signals and slows gastric emptying, which is the mechanism behind both the appetite suppression and most of the side effects.

Because Mounjaro and Zepbound are the same molecule, anything you read about how tirzepatide works, what it does to weight, or how it affects muscle applies equally to both brands.

Why two brand names for one drug?

This is the same playbook Novo Nordisk used with semaglutide, where Ozempic is the diabetes brand and Wegovy is the weight-management brand. We cover that parallel in Ozempic vs Wegovy.

Drugmakers brand the same molecule separately for different FDA-approved indications. A medication has to be approved for a specific use, and the approval, labeling, marketing, and often the dosing schedule are tied to that indication. Splitting one drug into two brands lets the manufacturer run separate trials, pricing, and insurance pathways for diabetes versus obesity.

For you, the practical upshot is that the brand you are prescribed usually reflects why you are being treated and what your insurance will cover, not a difference in the medicine itself.

Mounjaro vs Zepbound, side by side

The table below lays out where the two brands actually diverge. Note that the differences live in the label, coverage, and access columns, not in the drug.

Factor	Mounjaro	Zepbound
Active drug	Tirzepatide (dual GIP/GLP-1 agonist)	Tirzepatide (dual GIP/GLP-1 agonist)
Manufacturer	Eli Lilly	Eli Lilly
FDA-approved use	Type 2 diabetes	Chronic weight management; obstructive sleep apnea in adults with obesity
Route and frequency	Weekly subcutaneous injection	Weekly subcutaneous injection
Weight-loss data	Same molecule; SURMOUNT trials apply	Up to ~22.5% average at the highest dose (SURMOUNT-1)
Insurance angle	Often covered for diabetes	Coverage for weight management is improving but inconsistent
Side-effect profile	Tirzepatide GI profile	Same tirzepatide GI profile
Muscle-loss considerations	Same; depends on rate of loss and protein/training	Same; depends on rate of loss and protein/training

Sources: Mounjaro and Zepbound prescribing information (accessdata.fda.gov); SURMOUNT-1 (NEJM 2022, Jastreboff et al.).

What the weight-loss data shows

Because both brands are tirzepatide, the trial evidence is shared. In SURMOUNT-1, a 72-week randomized trial of adults with obesity or overweight without type 2 diabetes (NEJM 2022, Jastreboff et al.), tirzepatide produced mean weight loss of roughly 16.0% at the 5 mg dose, 21.4% at 10 mg, and 22.5% at 15 mg, versus about 2.4% with placebo. Roughly nine in ten participants on tirzepatide lost weight.

Those figures describe the molecule. Whether the pen is labeled Mounjaro or Zepbound does not change the underlying biology, though the dose strengths offered and the way the drug is titrated can vary by brand and indication. The actual schedule and dose are decisions for your prescriber, and we do not give titration instructions here.

For diabetes specifically, the SURPASS program established tirzepatide's effects on blood sugar; weight loss was a secondary benefit in that population.

Side effects are the same because the drug is the same

Both brands carry tirzepatide's side-effect profile, which skews gastrointestinal. In the SURMOUNT-1 trial, nausea, diarrhea, and constipation were the most common effects, and they tended to be most frequent during dose escalation before easing over time. For example, nausea was reported by roughly a quarter to a third of participants depending on dose, versus under 10% on placebo.

Switching from Mounjaro to Zepbound (or vice versa) at the same dose would not be expected to change your side effects, because you are taking the identical drug. If your tolerance shifts, it is usually about the dose or how fast you ramped, not the brand name. Our GLP-1 side effects complete guide covers what is common, what eases, and what warrants a call to your prescriber.

Dosing and availability nuances that do differ

Although the molecule is identical, the two brands are not always interchangeable in practice, and the differences are worth knowing.

Dose strengths and how the drug is supplied can vary by brand and indication. The two brands may not offer the exact same set of dose strengths at every point in time, and supply of specific strengths has fluctuated. That is a logistics reality, not a difference in the medicine, but it can affect which brand your pharmacy can actually fill.

Insurance is the other practical divider. A plan that covers tirzepatide for diabetes (Mounjaro) may not cover it for weight management (Zepbound), or may require a separate prior authorization. Because the two brands are billed against different approved uses, your coverage can hinge entirely on which brand is prescribed and why, even though the drug in the pen is the same.

The actual dose, the titration schedule, and any decision to move between strengths are matters for your prescriber and your label. We do not provide dosing instructions here; the point is simply that "same drug" does not always mean "same experience at the pharmacy counter."

The part the brand label ignores: your muscle

Here is the thread that runs under both brands. Tirzepatide is highly effective at producing rapid, large weight loss, and rapid weight loss always puts lean mass at risk alongside fat. Research suggests that roughly 25 to 40% of total weight lost on GLP-1 medications can come from lean mass, a category that includes water and organ mass, not only skeletal muscle. Tirzepatide trials tend toward the lower end of that range; the SURMOUNT-1 body-composition substudy (DOM 2025) found fat mass fell about 33.9% while lean mass fell about 10.9%, so the ratio shifted favorably toward fat loss overall.

That favorable ratio is not automatic, though. It depends on protein intake, resistance training, and not losing weight too fast. We unpack the numbers in how much muscle you lose on Ozempic and Wegovy, and the principles apply directly to tirzepatide.

Whether your pen says Mounjaro or Zepbound, Myo tracks the part the label leaves out: it logs your dose alongside lean mass, protein, and resistance training, so the brand on the box never decides whether you can see and protect your muscle. Myo is a tracking and education tool, not medical advice, and it is not affiliated with Eli Lilly.

So which one should you use?

You usually do not choose. Your prescriber selects the brand based on why you are being treated and what your coverage allows. If the goal is weight management, Zepbound is the on-label brand and the one most likely to be covered for that purpose; if you are being treated for type 2 diabetes, Mounjaro is the diabetes-indicated brand. Zepbound's additional approval for obstructive sleep apnea may also factor in for some patients.

The bottom line: Mounjaro and Zepbound are tirzepatide twins. The drug, the dosing route, the side effects, and the muscle-loss math are the same across both. What differs is the approved use, the insurance pathway, and the access. Pick the conversation with your prescriber over the brand on the box, and keep your protein and training steady regardless of which name is on the pen.

References

Tirzepatide as the active ingredient in both brands, and FDA-approved indications: Mounjaro and Zepbound prescribing information (accessdata.fda.gov).

Tirzepatide weight-loss magnitude (~16-22.5% by dose): SURMOUNT-1 (NEJM 2022, Jastreboff et al.); Lilly SURMOUNT-1 investor release.

Tirzepatide gastrointestinal side effects by dose: SURMOUNT-1 GI tolerability analysis (Diabetes, Obesity and Metabolism 2025, doi:10.1111/dom.16176).

Lean-mass share of weight lost and tirzepatide body composition: SURMOUNT-1 body-composition substudy (Diabetes, Obesity and Metabolism 2025, doi:10.1111/dom.16275).